Friess Associates LLC Coherus Bio Sciences, Inc. Call Options Transaction History
Friess Associates LLC
- $59.9 Million
- Q2 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CHRS
# of Institutions
133Shares Held
70MCall Options Held
1.16MPut Options Held
39.5K-
Black Rock Inc. New York, NY11.8MShares$13.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$13.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$6.23 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$6.21 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$4.31 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $91.7M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...